Compare Stocks → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEAMERICAN:ARMPNASDAQ:ARYDNASDAQ:CLLSNASDAQ:LJPC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARMPArmata Pharmaceuticals$2.53+1.2%$0.00$1.07▼$5.26$91.49M0.8517,071 shs4,671 shsARYDARYA Sciences Acquisition Corp IV$11.33-0.2%$11.26$10.41▼$11.39$85.43MN/A46,820 shs15,615 shsCLLSCellectis$2.49-0.4%$2.63$0.96▼$3.77$138.39M3.1240,396 shs14,710 shsLJPCLa Jolla Pharmaceutical$5.73$3.07▼$6.24$155.11M2.39158,476 shs66,708 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARMPArmata Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ARYDARYA Sciences Acquisition Corp IV0.00%+0.35%+0.80%+2.99%+9.13%CLLSCellectis-4.57%+1.63%-3.10%-10.39%+28.87%LJPCLa Jolla Pharmaceutical0.00%0.00%0.00%0.00%0.00%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARMPArmata Pharmaceuticals2.479 of 5 stars3.55.00.00.00.61.70.6ARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/AN/AN/AN/ACLLSCellectis2.4863 of 5 stars3.52.00.00.01.52.51.3LJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARMPArmata Pharmaceuticals3.00Buy$7.00176.59% UpsideARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/ACLLSCellectis3.00Buy$8.50241.37% UpsideLJPCLa Jolla PharmaceuticalN/AN/AN/AN/ACurrent Analyst RatingsLatest ARMP, ARYD, CLLS, and LJPC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024ARMPArmata PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARMPArmata Pharmaceuticals$4.53M20.20N/AN/A($0.89) per share-2.84ARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/A($3.49) per shareN/ACLLSCellectis$25.73M5.38N/AN/A$2.76 per share0.90LJPCLa Jolla Pharmaceutical$75.72M0.00N/A7.95($2.94) per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARMPArmata Pharmaceuticals-$69.04M-$1.98N/AN/AN/A-1,524.51%-280.95%-52.61%5/9/2024 (Estimated)ARYDARYA Sciences Acquisition Corp IV-$2.13MN/A0.00∞N/AN/A-9.83%-5.41%N/ACLLSCellectis-$106.14M-$1.67N/AN/AN/A-346.65%-73.03%-32.22%5/2/2024 (Estimated)LJPCLa Jolla Pharmaceutical$19.66M$0.1251.840.00N/A8.54%-5.46%4.00%N/ALatest ARMP, ARYD, CLLS, and LJPC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/21/2024Q4 2023ARMPArmata PharmaceuticalsN/A-$0.55-$0.55-$0.55$0.68 million$1.53 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARMPArmata PharmaceuticalsN/AN/AN/AN/AN/AARYDARYA Sciences Acquisition Corp IVN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/ALJPCLa Jolla PharmaceuticalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARMPArmata PharmaceuticalsN/A1.161.16ARYDARYA Sciences Acquisition Corp IVN/A0.010.01CLLSCellectis0.572.202.20LJPCLa Jolla PharmaceuticalN/A4.023.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARMPArmata Pharmaceuticals3.57%ARYDARYA Sciences Acquisition Corp IV48.08%CLLSCellectis63.90%LJPCLa Jolla Pharmaceutical97.06%Insider OwnershipCompanyInsider OwnershipARMPArmata Pharmaceuticals85.50%ARYDARYA Sciences Acquisition Corp IV53.45%CLLSCellectis16.41%LJPCLa Jolla Pharmaceutical36.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableARMPArmata Pharmaceuticals6636.15 million5.24 millionNot OptionableARYDARYA Sciences Acquisition Corp IV37.54 million3.51 millionNot OptionableCLLSCellectis23155.58 million46.46 millionOptionableLJPCLa Jolla Pharmaceutical6124.94 million15.89 millionOptionableARMP, ARYD, CLLS, and LJPC HeadlinesSourceHeadlineLa Jolla small business owners want lawful path to conduct business on the beachmsn.com - March 27 at 1:40 PMScripps Seaside Forumscripps.ucsd.edu - February 12 at 3:13 PMScripps Green Hospitalhealth.usnews.com - December 19 at 11:27 PM‘We may have to pull the plug’: La Jolla Christmas Parade running short of funds for Dec. 3 eventsandiegouniontribune.com - December 4 at 7:24 PM‘We lost all our fuel’: Pilot killed when small Cessna crashes in La Jollasandiegouniontribune.com - November 24 at 6:32 PMPilot killed in La Jolla neighborhood plane crash identified as Carlsbad mansandiegouniontribune.com - November 24 at 6:32 PMLa Jolla Halloween Events 2023: Trick-Or-Treats & Pumpkin Patchespatch.com - October 28 at 7:51 PMLa Jolla Pharmaceutical (NASDAQ: LJPC)fool.com - September 25 at 7:30 PMLa Jolla BJ's Hoppy Hawaiian Shirts To Benefit Maui Recovery Effortpatch.com - September 14 at 7:50 PMHepatorenal Syndrome Treatment Global Market Report 2023finance.yahoo.com - July 27 at 2:22 AMFireworks Near Me: La Jolla July 4th Events 2023patch.com - July 17 at 7:59 AMDonors Needed In La Jolla To Prevent Red Cross Blood Shortagepatch.com - July 15 at 8:21 AM2 La Jolla Students Receive 2023 National Merit Scholarshipspatch.com - July 15 at 1:10 AMJuly 4th Fireworks 2023 Near La Jollapatch.com - July 1 at 1:25 AMThalassemia Market Research | 2023-2030marketwatch.com - May 16 at 8:59 AMResults from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet ...businesswire.com - May 11 at 8:36 PMKidney (Renal) Fibrosis Market Report | Research Across The World 2031marketwatch.com - May 10 at 10:18 AMKidney Fibrosis Treatment Market Dynamics and Drivers: 2023-2031marketwatch.com - May 8 at 12:20 AMBased on recent market research, the Kidney/Renal Fibrosis Treatment market is set to experience robust growth, with a CAGR of 7% from 2023 to 2030.marketwatch.com - May 5 at 9:20 PMFibrodysplasia Ossificans Progressiva Drug Market Historical Trends and Future Prospect till 2031marketwatch.com - May 4 at 1:46 PMLa Jolla High Schoolusnews.com - May 3 at 10:44 PMLa Jolla aesthetician building confidence for homeless through nonprofitktvz.com - May 3 at 2:32 AMCan The Proposed Antibiotic For Multidrug-Resistant Infections Fuel Innoviva's Revenue Growth?markets.businessinsider.com - April 19 at 1:55 PMInnoviva Stock Trading Halted Todayjoplinglobe.com - April 17 at 10:08 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsArmata PharmaceuticalsNYSEAMERICAN:ARMPArmata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Los Angeles, California.ARYA Sciences Acquisition Corp IVNASDAQ:ARYDArya Sciences Acquisition Corp IV does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring North American or European companies in the life sciences and medical technology sectors. The company was incorporated in 2020 and is based in New York, New York.CellectisNASDAQ:CLLSCellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.La Jolla PharmaceuticalNASDAQ:LJPCLa Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases. The company offers GIAPREZA, a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock; and XERAVA, a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. It offers GIAPREZA and XERAVA to hospitals and other healthcare organizations in the United States. Its product candidates that are in early stage clinical or preclinical development include TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria; TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens, as well as bacterial pathogens associated with community-acquired bacterial pneumonia; and TP-2846, an IV formulation of a tetracycline for the treatment of acute myeloid leukemia. The company has license agreement with Everest Medicines Limited to develop and commercialize XERAVA; and PAION AG to commercialize GIAPREZA and XERAVA. La Jolla Pharmaceutical Company was incorporated in 1989 and is based in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.